The legal and regulatory picture for peptides is shifting fast through 2026–2027, and most of what is sold online is not FDA-approved. This silo explains the framework plainly, keeps a dated status of record, and never tells you to obtain or use anything. It is research and educational information, not legal or medical advice.
Start with the tracker
- 2026 Regulatory Tracker — the dated FDA / 503A / PCAC status of record for every peptide we cover (BPC-157, TB-500, GHK-Cu, retatrutide, and more). Updated as the FDA acts; next scheduled review after the July 23–24, 2026 PCAC hearing.
The explainers
- Are peptides legal? — the 503A bulk-substances framework, the April 2026 Category-2 removals, the PCAC reviews, and what they do and do not mean.
- “Research use only,” explained — what the RUO label legally is (a labeling category, not an FDA safety clearance), and the buyer-journey reality.
- Investigational vs approved — the four lanes a peptide can occupy: FDA-approved, investigational, compounded, and research-grade.
Why dates matter here
A peptide’s status can change with a single FDA action. Every regulatory statement on Peptevity carries a last-reviewed date and is sourced to the FDA or the Federal Register. When the July 2026 PCAC outcome lands, the tracker and the affected monographs are updated and the change is logged under our corrections policy.
Every claim above is cited inline to a primary source. See how we grade evidence and our sourcing & citation policy.